Ultime notizie per electroCore (NASDAQ:ECOR) Azioni

ELECTROCORE INC

electroCore

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

electroCore Inc

Elcora Advanced Materials Corp

ELCORA ADVANCED MATERIALS by Elcora Advanced Materials Corp.

ECORA RESOURCES U/ADR by ECORA RESOURCES PLC

ECORA RESOURCES PLC by ECORA RESOURCES PLC

Ecora Resources PLC

Citigroup analyst Scott Gruber upgrades RPC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) from Sell to Neutral and lowers the price target from $5.5 to $4.75.

News

Upgrades

Price Target

Analyst Ratings

Citigroup Upgrades RPC to Neutral, Lowers Price Target to $4.75

Contracts

AMPS

Altus Power Acquires Ten Maryland Community Solar Projects, Terms Not Disclosed

The United States Postal Service is rolling out sweeping changes to mail delivery, part of a 10-year "Delivering for America" plan that took effect on April 1. The moves aim to check mounting financial losses and improve efficiency but have sparked backlash from unions worried about potential service cuts.
What Happened: President Donald Trump's cost-cutting initiative, led by billionaire Elon Musk and his Department of Government Efficiency (DOGE), has not spared the USPS, which operates independently but remains subject to congressional oversight. The plan cuts roughly 10,000 jobs — about 1.5% of the workforce — and introduces a fleet of <a href="https://www.benzinga.com/24/12/42454670/usps-chief-defends-plan-to-buy-more-electric-delivery-vehicles-says-wont-return-funds-without-legislation-from-congress">electric delivery trucks</a> to replace aging vehicles.
Officials say the revisions will make some mail arrive faster while others might slow. According to USPS estimates, 75% of first-class mail will see no major change. Another 14% may arrive quicker, while 11% could take longer, though still within a one-to-five-day window. More details are expected on July 1, when the next phase of adjustments begins.
See also: <a href="https://www.benzinga.com/25/04/44681169/marvell-scores-25b-from-infineon-deal-exits-auto-ethernet-segment">Marvell Offloads Auto Ethernet Segment To Infineon Tech For $2.5 Billion Cash</a>
Why It Matters: Union leaders insist the postal service, older than the nation itself, shouldn't be <a href="https://about.usps.com/what/financials/integrated-financial-plans/fy2025.pdf">forced to turn a profit</a>. They warn that privatization — <a href="https://www.benzinga.com/markets/25/03/44163953/elon-musk-pushes-for-privatization-of-postal-service-and-amtrak-it-will-leave-you-with-a-very-bad-impression-of-america">floated by Musk</a> — could abandon rural communities, as private carriers often skip less profitable routes. Meanwhile, Trump has suggested <a href="https://www.benzinga.com/news/25/02/44026259/millions-rely-on-usps-trumps-plan-could-upend-1-2-trillion-in-mail-and-shipping">merging the USPS</a> with the Commerce Department to further centralize control.
Many Americans rely on daily mail for prescriptions, benefits, and crucial documents. Critics argue that excessive cuts threaten a national lifeline, while supporters say the reforms are long overdue. With job reductions already underway and more tweaks on the horizon, the Postal Service finds itself balancing economic realities against its mission to deliver mail to every corner of the country.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/markets/equities/25/04/44681205/gamestop-ceo-ryan-cohens-support-for-trump-faces-new-test-after-he-posts-10000-iphone-tweet-amid-market-turmoil-and-tariff-fallout">GameStop CEO Ryan Cohen&#8217;s Support For Trump Faces New Test After He Posts &#8216;$10,000 iPhone&#8217; Tweet Amid Market Turmoil And Tariff Fallout</a>

Equities

Government

Markets

USPS Overhaul Of Mail Delivery Services Already Underway — Here's What's Going To Change

MANCHESTER, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Pf48kbyNF9swKsK8ItopAut1eifYQWQwAhhHtRR0unwjBcEfTyNEJEudB9OMde9ACJRuGFoRMPh8MIcoI1RuOru8FvrvVHFYhtJe1ezInS3vxCQ0ifARHijnc9IP__ZBGv1DVfRCaXCCeWbQXYpn6PQtLpoAMjtzIjugBTZTsMZ6av-5w6T1CHtH1KPW1YxwRguIE8ZU5Dxg0dzT0FXbwJ3HbHHrn_uCfjZsKnu3KQSJeyWITXeh9zzv3VS_W_xtEIP3PXjyBPz1twrm2QusFNNgTgiU7udI1LMBIRD6l4Q=">Allegro MicroSystems, Inc.</a> ("Allegro") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>), a global leader in power and sensing solutions for motion control and energy-efficient systems, today announced three new solutions designed to enhance motor control and thermal management performance in e-mobility and industrial automation applications. These new solutions, the <a href="https://www.globenewswire.com/Tracker?data=-Z8y7wX0YO-_jAsbAWAS41CP9KBD0nOMZhrXMLZuA0KgrYLzC0reoMOV8ugeXlLzSqt3U5ZOWHztlA5v4WNPFAiqcJgzYNXurS6FLdRROi60auLEjjJ8_RRAuzbc3YUEj3eEtZr7jvmbHVREd1CoVt6YZliLoqqNGOy4XKg0cAjgd9eaMubwLPBfMNNt62dMJ-MUL5ZwfVfeX1puDZnJ28vsC_g_OPI98gX1zhUp-4oYyjxZbkf2T3aALNJ88D2ui8vLcJvwizt8S6Rq6WacrOpclXYuP-0PH2HpvOpP__aHFyR-YyuZLsuGEVx38DbxKHESUgFvZV3_oK2M-R5S13W_SqDFOVQdhjDj4LmGonE=">ACS37035</a> and <a href="https://www.globenewswire.com/Tracker?data=-Z8y7wX0YO-_jAsbAWAS46gS4zeJtTJRkFacoC_0JN5hr6oO1YDclvQqSFMDu81_Ie-CsXIXoCOi7EXr5kpc3F2epQncs9l3GMv_tT3w7SdoMIlTHvZw4m--NKl7w8MOp8aplxvePMwsYHn3KG2_zrg0Vlpl_PgTFbZWJtxJSuQiGPViiFeD-ryssuwbM1rZGxrsF_ajD9j5MP1TevPxM_cvvDEKieoaPvEeMeTPYmYuoRNEuf3jw1wG9i-PZXXEjOpx3MkVOE7lal1s8T8pJYeVEMI2cEezJ3NYqy6n4JNnvZfmyMBD7u0YjIo6qpWLkvi8Oj8An8FQAfXN8Pg5E64JeBqKarwE4ac6brgOgTw=">ACS37630</a> current sensors, and the <a href="https://www.globenewswire.com/Tracker?data=iWj7znqv6GwK6ewMEx-uoXw7NyRyUMlpApRih8MOSJhrBjFXSV6MaiQBbG8alK0wtHDt_gIn14PnaiskzdB3_tzHch_5Fva3WqUllCcJqmO4VkELvqwJEfThBllKm5yanWmdqGUOotRrO5V4MXZh2KBe1phs0fjWGpPwa6MwI-lL2N6tLBnqFOZ7_sYNAOo4nkiDPBrD1r-hb3evg6EswxnngRTbg3JyU5V7bktQX7XH6g5RL7lyIGcqPejDgxiWQQ4VX7OnzMnh6iITTj3yq22LSkbxVSsTM8slNuuBIYY=">A89347</a> automotive-grade fan driver IC, provide advanced capabilities for a wide range of applications.
"Our latest motor control and thermal management solutions reflect Allegro's commitment to delivering innovative technology that enhances efficiency and performance across automotive and industrial applications," said Ram Sathappan, Vice President of Global Marketing and Applications at Allegro. "The ACS37035 and ACS37630 provide industry-leading accuracy and noise immunity for precise motor control for demanding applications such as robots, industrial motors and electric vehicle traction inverters. The A89347 fan driver IC ensures quiet, reliable operation in seat- and battery-cooling applications in the e-mobility space. We are excited to highlight these products as a forward-looking solution for simplifying design, improving overall system efficiency, and empowering our customers to innovate and deliver exceptional value."

ALGM

Allegro MicroSystems Announces Expansion Of Motor Control And Thermal Management Solutions

Throughout the last three months, 5 analysts have evaluated Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $151.4, along with a high estimate of $155.00 and a low estimate of $150.00. Marking an increase of 16.82%, the current average surpasses the previous average price target of $129.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113714_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Palomar Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jimmy Bhullar &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $150.00&#x7C;$115.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Outperform &#x7C; $155.00&#x7C;$152.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Outperform &#x7C; $152.00&#x7C;$136.00 &#x7C; 
&#x7C;Mark Hughes &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $150.00&#x7C;$112.00 &#x7C; 
&#x7C;Paul Newsome &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $150.00&#x7C;$133.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Palomar Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Palomar Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Palomar Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Palomar Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PLMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Palomar Hldgs analyst ratings.</a>
<h2>Unveiling the Story Behind Palomar Hldgs</h2>
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.
<h3>Breaking Down Palomar Hldgs's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Palomar Hldgs's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 47.78%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Palomar Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.47% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Palomar Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Palomar Hldgs's ROA excels beyond industry benchmarks, reaching 1.54%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Palomar Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLMR

5 Analysts Have This To Say About Palomar Hldgs

Biotech

General

RXRX

Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of REC-3565 For Relapsed Or Refractory B-cell Lymphomas

Barclays analyst Christine Cho downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Overweight to Equal-Weight and lowers the price target from $9 to $5.

Downgrades

FLNC

Barclays Downgrades Fluence Energy to Equal-Weight, Lowers Price Target to $5

Across the recent three months, 8 analysts have shared their insights on Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Praxis Precision Medicine and provided 12-month price targets. The average target is $108.62, accompanied by a high estimate of $175.00 and a low estimate of $73.00. Experiencing a 19.71% decline, the current average is now lower than the previous average price target of $135.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113687_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Praxis Precision Medicine. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $85.00&#x7C;$85.00 &#x7C; 
&#x7C;Joon Lee &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $85.00&#x7C;$175.00 &#x7C; 
&#x7C;Joel Beatty &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $73.00&#x7C;$117.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $85.00&#x7C;$150.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $105.00&#x7C;$120.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $111.00&#x7C;- &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $150.00&#x7C;$150.00 &#x7C; 
&#x7C;Joon Lee &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $175.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Praxis Precision Medicine. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Praxis Precision Medicine compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Praxis Precision Medicine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Praxis Precision Medicine's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRAX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Praxis Precision Medicine analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Praxis Precision Medicine</h2>
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
<h3>Praxis Precision Medicine: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Praxis Precision Medicine's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1349.13% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Praxis Precision Medicine's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -786.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.17%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Praxis Precision Medicine's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Praxis Precision Medicine's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRAX

Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)

Copper experienced one of the <a target="_blank" href="https://www.benzinga.com/25/04/44663034/asia-in-freefall-hang-seng-posts-worst-drop-since-1997-europe-market-tumbles-oil-slips-gold-eases-global-markets-today-while-us-slept" rel="noreferrer noopener">most volatile trading days</a> in over 15 years, tumbling as much as 7.7% at the start of Monday's trading session in London.
Three-month contracts slid to $8,780 a ton as investors scrambled to reduce exposure—before staging a nearly $1,000 rebound in just over two hours—marking the largest intraday price swing since 2009.
"Metals are under significant pressure from dampened sentiment as the world braces for a possible recession and heightened geopolitical tensions that would threaten demand," Sabrin Chowdhury, head of commodities at BMI, said <a target="_blank" href="https://www.bnnbloomberg.ca/tariffs/2025/04/06/gold-falls-further-at-open-as-traders-assess-tariff-turmoil/" rel="noreferrer noopener">per</a> Bloomberg.
Copper's volatility recently surged as President Donald Trump's tariff threat hit both sides of the spectrum. The market rallied sharply in anticipation as the threat of copper being added to the list of targeted metals <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44498083/trumps-copper-tariffs-might-come-sooner-rather-than-later-insiders-warn" rel="noreferrer noopener">loomed in March</a>.
Traders raced to reroute shipments to the U.S., capitalizing on a premium in New York prices – even yesterday's selloff saw New York prices hovering much higher, around $10,000 per ton.
However, a possible recession quenched speculators' short-term thirst, as copper exceeded the broad sector decline before buyers stepped in to reverse the course. For Codelco chairman Maximo Pacheco, the logic behind the dip buying is obvious.
The fundamentals haven't changed at all," he <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-07/codelco-boss-keeps-faith-in-copper-fundamentals-amid-market-rout" rel="noreferrer noopener">said</a>, citing sustained Chinese interest and a resilient U.S. market. China has been a notable copper buyer in times of price crunches, stepping in to recover the market in 2008 and 2020.
Codelco, the world's top copper supplier, plans to invest up to $5.6 billion in 2025 to rejuvenate aging mines and restore output to pre-2020 levels. The Chilean state-owned giant is also expanding into lithium, aiming to finalize a <a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/42840568/chiles-codelco-targets-turnaround-with-modest-copper-output-increase-and-strategic-lithium-ventures" rel="noreferrer noopener">key deal with </a><a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/42840568/chiles-codelco-targets-turnaround-with-modest-copper-output-increase-and-strategic-lithium-ventures" rel="noreferrer noopener">SQM</a><a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/42840568/chiles-codelco-targets-turnaround-with-modest-copper-output-increase-and-strategic-lithium-ventures" rel="noreferrer noopener"> by Q3</a>.
The tariff uncertainty dominated discussions at this week's CESCO conference in Santiago, where Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) CEO Kathleen Quirk warned that trade wars could "cause people to not invest, to not buy, to change their patterns and affect demand."
Last month, Quirk noted that tariffs could boost her company's <a target="_blank" href="https://www.benzinga.com/25/03/44271394/goldman-sees-copper-imports-frontrunning-tariffs-as-fcx-positions-to-benefit" rel="noreferrer noopener">annual profits by $500 million</a>, but she's well aware that the long-term industry outlook stretches beyond the short-term profit.
"All of us will rely on a market that will be growing in demand and not subject to these big recessions that we've seen over time," she said, according <a target="_blank" href="https://www.reuters.com/markets/commodities/freeport-mcmoran-ceo-flags-concern-over-global-growth-amid-us-tariffs-2025-04-07/" rel="noreferrer noopener">to</a> Reuters, recalling the effects of the Great Recession.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/44663078/barrick-gold-proposes-name-change-targets-30-production-growth-by-2030" target="_blank" rel="noreferrer noopener">Barrick Gold Proposes Name Change, Targets 30% Production Growth By 2030</a></li>
</ul>
Photo via Shutterstock

Financing

Commodities

Politics

Global

Media

COPX

CPER

JJCTF

JJMTF

Copper's Rout Sees A Massive Intraday Price Swing, 'Fundamentals Haven't Changed,' Expert Says

Accenture Federal Services Launches Managed Extended Detection And Response (MxDR) Solution With Google Public Sector

Analysts' ratings for Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Legend Biotech and provided 12-month price targets. The average target is $75.2, accompanied by a high estimate of $80.00 and a low estimate of $73.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113672_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Legend Biotech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $80.00&#x7C;$82.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $75.00&#x7C;$73.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $73.00&#x7C;$73.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $73.00&#x7C;$73.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Legend Biotech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Legend Biotech compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Legend Biotech's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Legend Biotech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LEGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Legend Biotech analyst ratings.</a>
<h2>All You Need to Know About Legend Biotech</h2>
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
<h3>Legend Biotech: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Legend Biotech showcased positive performance, achieving a revenue growth rate of 134.73% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Legend Biotech's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Legend Biotech's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Legend Biotech's ROA stands out, surpassing industry averages. With an impressive ROA of 1.54%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Legend Biotech's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LEGN

5 Analysts Have This To Say About Legend Biotech

Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Weyerhaeuser, presenting an average target of $34.25, a high estimate of $36.00, and a low estimate of $31.00. This current average has decreased by 7.43% from the previous average price target of $37.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113647_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Weyerhaeuser among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Hong Zhang &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $31.00&#x7C;- &#x7C; 
&#x7C;Matthew McKellar &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Anthony Pettinari &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $35.00&#x7C;$38.00 &#x7C; 
&#x7C;Hamir Patel &#x7C;CIBC &#x7C;Announces &#x7C;Outperformer &#x7C; $35.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Weyerhaeuser. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Weyerhaeuser compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Weyerhaeuser's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Weyerhaeuser's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Weyerhaeuser analyst ratings.</a>
<h2>About Weyerhaeuser</h2>
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
<h3>Weyerhaeuser: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Weyerhaeuser's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.72%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Weyerhaeuser's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Weyerhaeuser's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.82%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Weyerhaeuser's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.49%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Weyerhaeuser adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Weyerhaeuser Stands With Analysts

Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), operating as a real estate investment trust, is one of the world&#8217;s largest private owners of timberlands. The company owns or controls approximately 10.4 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada.
It will report its Q1 2025 earnings on April 24. Wall Street analysts expect the company to post EPS of $0.16, matching the figure in the year-ago period. According to data from Benzinga Pro, quarterly revenue is expected to be $1.84 billion, up from $1.80 billion a year earlier.
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
The 52-week range of Weyerhaeuser stock price was $26.73 to $35.30.
Weyerhaeuser dividend yield is 3.06%. It paid $0.84 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On Weyerhaeuser</h2>
On Jan. 30, the company announced its Q4 2024 earnings, posting adjusted EPS of $0.11, beating the consensus estimate of $0.07, and revenues of $1.71 billion, in line with expectations, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43353549/weyerhaeuser-q4-adj-0-11-beats-0-07-estimate-sales-1-71b-inline">Benzinga</a>.
"Our performance in 2024 reflects solid execution against a challenging market backdrop," said CEO Devin W. Stockfish.
"Entering 2025, our balance sheet is strong, and we are well positioned to capitalize as market conditions improve. We remain focused on achieving our multi-year targets, serving our customers and driving long-term value for our shareholders," he added.
Check out this <a href="https://www.benzinga.com/insights/short-sellers/25/04/44628930/how-is-the-market-feeling-about-weyerhaeuser">article by Benzinga</a> to learn how the market is feeling about Weyerhaeuser?
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As A Weyerhaeuser Investor?</h2>
If you want to make $100 per month — $1,200 annually — from Weyerhaeuser dividends, your investment value needs to be approximately $39,216, which is around 1,430 shares at $27.43 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.06% in this case). So, $1,200 / 0.0306 = $39,216 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find Weyerhaeuser stock an attractive option for making a steady income of $100 per month by owning 1,430 shares of stock.&nbsp;
Read Next:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

How To Put $100 In Your Retirement Fund Each Month With Weyerhaeuser Stock

Throughout the last three months, 14 analysts have evaluated Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $128.64, a high estimate of $150.00, and a low estimate of $100.00. This current average has increased by 0.63% from the previous average price target of $127.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113635_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Blueprint Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Michael Yee &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $135.00&#x7C;- &#x7C; 
&#x7C;Louise Chen &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $150.00&#x7C;- &#x7C; 
&#x7C;Reni Benjamin &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $135.00&#x7C;$135.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Brian Cheng &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $129.00&#x7C;$126.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $119.00&#x7C;$109.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;David Nierengarten &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $124.00&#x7C;$135.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $135.00&#x7C;$135.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Blueprint Medicines. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Blueprint Medicines's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blueprint Medicines's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
<h3>Blueprint Medicines's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Blueprint Medicines displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 103.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -34.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -16.33%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Blueprint Medicines's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.57, Blueprint Medicines faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

Breaking Down Blueprint Medicines: 14 Analysts Share Their Views

Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Dominion Energy, presenting an average target of $58.5, a high estimate of $63.00, and a low estimate of $52.00. A 0.43% drop is evident in the current average compared to the previous average price target of $58.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744113621_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Dominion Energy among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jeremy Tonet &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $52.00&#x7C;$59.00 &#x7C; 
&#x7C;Ross Fowler &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $60.00&#x7C;$58.00 &#x7C; 
&#x7C;Stephen Byrd &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $63.00&#x7C;$60.00 &#x7C; 
&#x7C;Jeremy Tonet &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $59.00&#x7C;$58.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dominion Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dominion Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dominion Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dominion Energy's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/D/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dominion Energy analyst ratings.</a>
<h2>Get to Know Dominion Energy Better</h2>
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
<h3>Dominion Energy's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3M period, Dominion Energy faced challenges, resulting in a decline of approximately -3.79% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.
Net Margin: Dominion Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dominion Energy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.38%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dominion Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Dominion Energy's debt-to-equity ratio is below the industry average. With a ratio of 1.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Dominion Energy Stock

Major Social Security updates, now in effect as of April 2025, stand to reshape benefits for millions of Americans. From bigger checks to new identification rules, these changes <a href="https://www.benzinga.com/personal-finance/25/01/42850946/planning-your-retirement-new-changes-to-social-security-in-2025-could-affect-you">could have a serious impact</a> on the paychecks of retirees, survivors, and those on spousal benefits.
<h3 class="wp-block-heading">What Changes Are Set To Be Underway?</h3>
<ul>
<li>The Social Security Fairness Act, <a href="https://www.benzinga.com/personal-finance/25/01/42935393/millions-of-public-employees-to-see-boosted-social-security-payments-after-biden-signed-social-security-fairness-act-into-law">signed in January</a>, repeals the Windfall Elimination Provision (WEP) and Government Pension Offset (GPO), boosting monthly checks for an estimated 3.2 million beneficiaries. Retired workers gain an average of $360, while spousal beneficiaries see around $700 extra. Widow or widower benefits may rise by roughly $1,190. Some recipients got retroactive pay in March; others should see higher amounts with their April payment.</li>
</ul>
<ul>
<li>On April 14, stricter identity verification kicks in. Those who&#8217;ve been making changes over the phone or by mail must appear in person to confirm their ID. However, applications for Medicare, disability, or Supplemental Security Income (SSI) remain exempt from this requirement.</li>
</ul>
See also: <a href="https://www.benzinga.com/25/04/44681272/jim-cramer-questions-market-strength-amid-chinas-retaliatory-tariffs-oversold-panic-or-a-big-trap">Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: &#8216;Is It All A Big Trap?&#8217;</a>
<ul>
<li>Another shift is the faster handling of direct deposit changes. Updates made via my Social Security account now process within one business day — far quicker than the previous 30-day wait. Phone requests are allowed until April 14, after which in-person verification becomes mandatory.</li>
</ul>
<ul>
<li>Overpayment recovery also reverts to a 100% rate under the Trump administration's directive, meaning entire checks could be withheld until debts are cleared. Older cases still follow a 10% cap, and SSI recipients remain unaffected.</li>
</ul>
<ul>
<li>Eligibility rules are unchanged: workers 62 or older with at least 10 years of employment still qualify. Meanwhile, the maximum monthly benefit — if you delay until 70 — can climb to $5,180.</li>
</ul>
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/04/44680956/billionaire-banker-backs-trumps-shock-and-awe-tariff-policies-slams-bill-ackmans-call-for-90-day-pause">Billionaire Banker Backs Trump&#8217;s &#8216;Shock And Awe&#8217; Tariff Policies, Slams Bill Ackman&#8217;s Call For 90-Day Pause</a>

April's Social Security Changes: How New Rules Could Affect Your Check

Barclays analyst Terry Ma upgrades Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) from Underweight to Equal-Weight and raises the price target from $10 to $14.

Barclays Upgrades Rocket Companies to Equal-Weight, Raises Price Target to $14

Barclays analyst Benjamin Budish reinstates AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) with a Equal-Weight and announces $34 price target.

Initiation

Barclays Reinstates Equal-Weight on AllianceBernstein Holding, Announces $34 Price Target

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and increased the price target from $25 to $28 on Oct. 30, 2024. This analyst has an accuracy rate of 73%.</li>
<li>B. Riley Securities analyst Lee Krowl reiterated a Buy rating and raised the price target from $24 to $25 on Oct. 30, 2024. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: On Feb. 27, Opera reported better-than-expected fourth-quarter revenue results and issued first-quarter revenue guidance above estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">latest OPRA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="916" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033544/image-32.png" alt="" class="wp-image-861318" style="width:474px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033544/image-32.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033544/image-32-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033544/image-32-768x693.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</h3>
<ul>
<li>Dividend Yield: 5.25%</li>
<li>Goldman Sachs analyst Toshiya Hari maintained a Neutral rating and slashed the price target from $92 to $70 on Feb. 6, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Ruben Roy downgraded the stock from Buy to Hold and cut the price target from $105 to $62 on Feb. 6, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: On Feb. 5, Skyworks issued second-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">latest SWKS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="906" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033624/image-33.png" alt="" class="wp-image-861325" style="width:489px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033624/image-33.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033624/image-33-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033624/image-33-768x700.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</h3>
<ul>
<li>Dividend Yield: 4.19%</li>
<li>B of A Securities analyst Mehdi Hosseini maintained a Buy rating and cut the price target from $130 to $112 on March 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li>UBS analyst Timothy Arcuri maintained a Neutral rating and increased the price target from $95 to $105 on Jan. 22, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On March 31, Seagate reported that it has completed the acquisition of Intevac.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest STX <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="902" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033707/image-34.png" alt="" class="wp-image-861337" style="width:507px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033707/image-34.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033707/image-34-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08033707/image-34-768x711.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678097/walgreens-rpm-international-and-3-stocks-to-watch-heading-into-tuesday">Walgreens, RPM International And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Trading Ideas

OPRA

SWKS

Wall Street's Most Accurate Analysts Spotlight On 3 Tech Stocks Delivering High-Dividend Yields

Leerink Partners analyst Faisal Khurshid initiates coverage on Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) with a Outperform rating and announces Price Target of $45.

SYRE

Leerink Partners Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $45

Press Releases

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Legal

electroCore Expands Intellectual Property Portfolio

electroCore's Truvaga™ Now Available on Amazon®

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal

electroCore to Participate at Upcoming Investor Conferences

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

Earnings

electroCore Announces Full Year 2024 Financial Results

electroCore Extends VA Contract for Five Years

electroCore to Participate at the Needham Virtual Healthcare Conference

electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times

ECOR

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

HeartBeam

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

Daxor

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

electroCore

Notizie

Ultime notizie per electroCore (NASDAQ:ECOR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO